Vega MLC, Mata AJA

Language: Spanish
References: 20
Page: 51-59
PDF size: 309.79 Kb.

ABSTRACT

Cervical cancer has been one of the most studied neoplastic lesions in the female population. Its behavior, epidemiology, histology, pathophysiology, clinical manifestations and natural history are clearly identified. It is characterized by generally slow evolution, which begins as a precancerous condition called dysplasia, which is detected by a Pap smear and may be treatable in one hundred percent of the cases. Cervical cancer worldwide is second in both incidence and mortality. Costa Rica ranks second in incidence and fourth in mortality. Nationally Pococí Canton ranks first in incidence and sixth in mortality, the canton of Guácimo is seventh and fifth in incidence and mortality, respectively. There are several risk factors associated with the development of cervical neoplasia. However, oncogenic HPV infection is a necessary cause for the development of cervical cancer, as there is a definite causal relationship with this virus.

REFERENCES

1. Análisis de Indicadores de Género y Salud en Costa Rica. En: Patricia Allen. Organización Panamericana de la Salud. 2004:1-15.

2. Análisis de la situación de cáncer cervicouterino en América Latina y el Caribe. En: Merle Lewis, PHD. Organización Panamericana de la Salud. 2004:1-33.

3. Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55:244–265.

4. Castle P, Schiffman M, Wheeler C, Wentzensen N, Gravitt P. Impact of improved classification of human papillomavirus with cervical precancer. Am J Epidemiol. 2010; 171:155-163.

5. Castle P. Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening?. Am J Epidemiol. 2008; 168:138- 144.

6. Dannecker C, Siebert U, Thaler C, Kiermeir D, Hepp H, Hillemanns P. Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics. Annals of Oncology. 2004;15:863-869.

7. DeCherney A. Diagnóstico y tratamiento ginecoobstétricos. 8a. ed. México. Editorial Manual Moderno, 2003.

8. Farjadian S, Asadi E, Doroudchi M, Samsami A, Tabei SZ, Kumar VP, et al. High risk HPV types in southern Iranian patients with cervical cancer. Pathology Oncology Research. 2003; 9(2):121-125.

9. Incidencia y mortalidad del cáncer en Costa Rica 1990-2003. En: Adolfo Ortiz B. Dirección de Vigilancia de la Salud. Ministerio de Salud. 2005:31-35.

10. Koshiol J, Lindsay L, Pimenta J, Poole C, Jenkins D, Smith J. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and metaanalysis. Am J Epidemiol. 2008; 168:123-137.

11. Mayrand M, Duarte E, Rodrígues I, Walter S, Hanley J, Ferenczy A. et al. Human papillomavirus DNA versus papanicolaou screening test for cervical cancer. N Engl J Med. 2007; 357(17): 1579-1588.

12. Molano M, van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, et al. Determinants of clearence of human papillomavirus infections in Colombian women with normal cytology: a populationbased, 5 years follow-up study. Am J Epidemiol. 2003; 158:486-494.

13. Muñoz N, Bosch F. Xavier, de Sanjosé S, Herrero R, Castellsagué X, Shah K, et al. Epidemiologic classification of human papillomavirus types VEGA, MATA: COMPORTAMIENTO DE LA PATOLOGÍA CERVICOUTERINA EN EL HOSPITAL DE GUÁPILES 59 associated with cervical cancer. N Engl J Med. 2003; 348(6): 518-527.

14. Nazzal O, Suárez E, Larraguibel R, Rojas L, Bronda A. Lesiones preinvasoras de cuello uterino: una visión actual. Rev Chil Obstet Ginecol. 2006; 71(5): 341-348.

15. S Abd El All H, Refaat A, Dandash K. Prevalence of cervical neoplastic lesions and human papiloma virus infection in Egypt: National cervical cancer screening project. Infectious agents and cancer. 2007; 2(17):1-14.

16. Sankaranarayan R, Nene Bhagwan, Shastri S, Jayant K, Muwonge R, Budukh A. et al. HPV screening for cervical cancer in rural Indica. N Engl J Med. 2009; 360(14): 1385- 1394.

17. Schiffman M, Herrero R, Hildesheim A, Sherman M, Bratti M, Wacholder S, et al. HPV DNA testing in cervical cancer screening results from women in a high-risk province of Costa Rica. JAMA. 2000; 283(1): 87-93.

18. Tumores malignos frecuentes en Costa Rica. En: Warry Jiménez. Módulo Once. Curso Especial de Posgrado en Atención Primaria para Médicos Generales. 1ra edición. San José, C.R.: EDNASSS-CCSS, 2004:1-38.

19. Ulate H, Alfaro Ricardo. Incidencia de citologías cervicales alteradas en mujeres menores de 20 años, en el Área de Salud de Paso Ancho- San Sebastián entre el 2006 y el 2020. Revista Médica de Costa Rica y Centroamérica LXVIII. 2011;596:127-131.

20. Usandizaga J. Obstetricia y Ginecología. España. Editorial Marbán Libros, S.L., 2010.